New hope for glioblastoma: personalized drug combo enters clinical trial
NCT ID NCT07391215
Summary
This trial is testing whether adding a new drug called paxalisib to standard chemotherapy (temozolomide) can better control aggressive brain tumors called glioblastoma. It will enroll about 64 adults whose tumors have specific genetic features. The main goals are to see if the combination is safe and if it can slow or stop tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal Marden NHS Foundation Trust
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.